BioCentury
ARTICLE | Clinical News

Aldeyra planning Phase III program for dry eye disease therapy

September 28, 2018 5:33 PM UTC

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) reported that reproxalap (ADX-102) significantly reduced ocular dryness and discomfort in a Phase IIb trial to treat dry eye disease. The company plans to start Phase III testing of the candidate next year.

The double-blind, U.S. trial enrolled 300 patients to receive 0.1% or 0.25% concentrations of reproxalap topical ophthalmic solution four times per day for 12 weeks or vehicle solution. The 0.25% concentration of reproxalap significantly reduced Four-Symptom Ocular Dryness Score and Overall Ocular Discomfort Symptom Score from baseline to week 12 vs. vehicle (p<0.05 for both). Aldeyra said symptom improvements greater than that of vehicle were observed as early as two weeks. The higher dose also significantly improved patients’ ocular fluorescein staining score vs. vehicle (p<0.05)...

BCIQ Company Profiles

Aldeyra Therapeutics Inc.